Citigroup Maintains Sell on Atara Biotherapeutics, Lowers Price Target to $1.4
Portfolio Pulse from Benzinga Newsdesk
Citigroup analyst Yigal Nochomovitz maintains a 'Sell' rating on Atara Biotherapeutics (NASDAQ:ATRA) and has lowered the price target from $2 to $1.4.
August 21, 2023 | 11:43 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Citigroup has maintained a 'Sell' rating on Atara Biotherapeutics and lowered the price target from $2 to $1.4.
The 'Sell' rating maintained by Citigroup and the lowering of the price target indicates a negative outlook for Atara Biotherapeutics. This could potentially lead to a decrease in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100